The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer's perspective [0.03%]
在厄瓜多尔基多市多发性硬化症患者中奥法木单抗的预算影响研究---从支付者的角度分析
Luis J Pastor-Quirós,Edgar P Correa-Díaz
Luis J Pastor-Quirós
Introduction: Multiple sclerosis is a neurological condition that causes disabilities and is most common in young adults. It imposes high financial costs affecting the quality of life of patients, families, and society. I...
Il futuro dei Fondi per Farmaci Innovativi: risultati di uno studio basato su Delphi panel [0.03%]
创新药物基金的未来：基于德尔菲小组的研究结果
Claudio Jommi,Patrizio Armeni,Arianna Bertolani et al.
Claudio Jommi et al.
Analisi di Budget Impact della formulazione depot di buprenorfina a rilascio prolungato per la gestione di pazienti affetti da disturbo da uso di oppiacei [0.03%]
长效布普瑞芬 Depot配方对患有阿片类药物使用障碍的患者的预算影响分析
Michele Basile,Lorenzo Somaini,Americo Cicchetti
Michele Basile
Real-world data: come possono aiutare a migliorare la qualità dell’assistenza [0.03%]
真实世界数据：它们如何帮助提高医疗质量
Giovanni Corrao,Giovanni Alquati,Giovanni Apolone et al.
Giovanni Corrao et al.
Analisi di Budget Impact di ponatinib per il management di pazienti affetti da leucemia mieloide cronica [0.03%]
Ponatinib用于管理慢性髓性白血病患者的预算影响分析
Michele Basile,Filippo Rumi,Americo Cicchetti
Michele Basile
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus [0.03%]
专家小组Delphi共识在2021年和2023年多发性骨髓瘤新型药物治疗中的地位
Boccadoro Mario,Berto Patrizia,Bringhen Sara et al.
Boccadoro Mario et al.
Introduction: The objective of this study was to understand the potential use of single agents and drug combinations in multiple myeloma (MM) across treatment lines in the years 2021 and 2023. ...
A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen [0.03%]
新型基因沉默治疗药物Patisiran和Inotersen的国际卫生技术评估比较分析
Sergio Iannazzo
Sergio Iannazzo
Objectives: Using the case study of patisiran and inotersen, we conducted a narrative comparative analysis of the health technology assessment (HTA) agency appraisals of these two first-in-class transthyretin gene silence...
Carcinoma a cellule renali metastatico: evidenze real-world da un ampio database amministrativo italiano [0.03%]
肾细胞癌的转移：来自一个广泛的意大利管理数据库的真实世界证据
Giulia Ronconi,Letizia Dondi,Carlo Piccinni et al.
Giulia Ronconi et al.